Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

por Warkentin, Alexander A, Lopez, Michael S, Lasater, Elisabeth A, Lin, Kimberly, He, Bai-Liang, Leung, Anskar YH, Smith, Catherine C, Shah, Neil P, Shokat, Kevan M
Publicado 2014

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

por Mali, Raghuveer Singh, Zhang, Qi, DeFilippis, Rosa Anna, Cavazos, Antonio, Kuruvilla, Vinitha Mary, Raman, Jayant, Mody, Vidhi, Choo, Edna F., Dail, Monique, Shah, Neil P., Konopleva, Marina, Sampath, Deepak, Lasater, Elisabeth A.
Publicado 2020

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

por Ciceri, Pietro, Müller, Susanne, O’Mahony, Alison, Fedorov, Oleg, Filippakopoulos, Panagis, Hunt, Jeremy P., Lasater, Elisabeth A., Pallares, Gabriel, Picaud, Sarah, Wells, Christopher, Martin, Sarah, Wodicka, Lisa M., Shah, Neil P., Treiber, Daniel K., Knapp, Stefan
Publicado 2014

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

por Larrayoz, Marta, Garcia-Barchino, Maria J., Celay, Jon, Etxebeste, Amaia, Jimenez, Maddalen, Perez, Cristina, Ordoñez, Raquel, Cobaleda, Cesar, Botta, Cirino, Fresquet, Vicente, Roa, Sergio, Goicoechea, Ibai, Maia, Catarina, Lasaga, Miren, Chesi, Marta, Bergsagel, P. Leif, Larrayoz, Maria J., Calasanz, Maria J., Campos-Sanchez, Elena, Martinez-Cano, Jorge, Panizo, Carlos, Rodriguez-Otero, Paula, Vicent, Silvestre, Roncador, Giovanna, Gonzalez, Patricia, Takahashi, Satoru, Katz, Samuel G., Walensky, Loren D., Ruppert, Shannon M., Lasater, Elisabeth A., Amann, Maria, Lozano, Teresa, Llopiz, Diana, Sarobe, Pablo, Lasarte, Juan J., Planell, Nuria, Gomez-Cabrero, David, Kudryashova, Olga, Kurilovich, Anna, Revuelta, Maria V., Cerchietti, Leandro, Agirre, Xabier, San Miguel, Jesus, Paiva, Bruno, Prosper, Felipe, Martinez-Climent, Jose A.
Publicado 2023